How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Atopic Dermatitis · investigational in the US · Featured evidence · 2 Myelofibrosis · investigational in the US · Featured evidence · 1 Alopecia Areata · investigational in the US · Featured evidence · 1 investigational in the US Featured evidence · 2
Trial Phase Endpoint Key result Signal Source NCT05526222
NCT05526222 · Atopic Dermatitis
This multicentre, randomized, double-blind, placebo-controlled Phase 3 study randomized 443 adults with moderate-to-severe atopic dermatitis to gecacitinib (jaktinib) 75 mg twice daily, 100 mg twice daily or placebo. Its two primary endpoints were the share of patients with EASI-75 and with IGA 0/1 at week 16. Both doses were significantly better than placebo on both endpoints (p<0.0001), so the primary endpoints were met. The figures come from Zelgen's own topline announcement of 13 April 2026; response rates have not been published.
3 The efficacy in the treatment of moderate and severe atopic dermatitis (16 weeks); The efficacy in the treatment of moderate and severe atopic dermatitis (16 weeks)2025-08-05
Co-primary endpoints at week 16, EASI-75 and IGA 0/1 (score 0 or 1 with at least a 2-point fall): both gecacitinib (jaktinib) 75 mg BID and 100 mg BID groups significantly higher than placebo, p<0.0001 (443 patients randomized to the two doses or placebo). The company release gives no response rates.
View full result not yet graded link ↗
View 1 more trial NCT04539639
NCT04539639 · Atopic Dermatitis
The study was randomized, double-blind, and placebo-controlled with 166 participants, and it used a validated clinical disease-activity measure as its primary endpoint. However, the primary comparison cannot be judged because results have not been posted, so the evidence remains limited despite the strong trial design.
2 Percentage of Participants Achieving at least a 50% Reduction in Eczema Area and Severity Index (EASI 50) from Baseline (At Week 12)2022-05-19
Results not posted; external-source review pending Partial signal link ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
All indications (49) Alopecia Areata (4) Atopic Dermatitis (4) Myelofibrosis (12) Other / comorbidity (29)
Phase 3 (7) Alopecia Areata
NCT05255237 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2022-03-25 – 2024-06-28 · Alopecia Areata
What this study did
NCT05051761 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-09-04 – 2023-12-27 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT05676242 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2023-01-11 – 2026-03-12 · Atopic Dermatitis
What this study did
NCT05526222 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2022-07-14 – 2025-08-05 · Atopic Dermatitis
What this study did
Myelofibrosis
NCT04617028 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-02-05 – 2023-10-18 · Myelofibrosis
What this study did
Other / comorbidity
NCT05861128 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2023-11-10 – 2026-03-04 · Ankylosing Spondylitis
What this study did
NCT05861102 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2023-07-20 – 2025-06-09 · Ankylosing Spondylitis
What this study did
Phase 2 (18) Alopecia Areata
NCT04034134 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2019-11-18 – 2021-11-26 · Alopecia Areata
What this study did
Atopic Dermatitis
NCT04539639 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-12-02 – 2022-05-19 · Atopic Dermatitis
What this study did
Myelofibrosis
NCT07471503 · Institute of Hematology & Blood Diseases Hospital, China
2026-03-16 – 2030-04-01 · Myelofibrosis (MF), HSCT
What this study did
NCT07938580 · Peking Union Medical College Hospital
2026-11 – 2029-12 · Myelofibrosis
What this study did
NCT04851535 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-07-28 – 2022-11-01 · Myelofibrosis
What this study did
NCT04217993 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-01-07 – 2022-08-03 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
What this study did
NCT03886415 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2019-01-08 – 2021-02-02 · Myelofibrosis
What this study did
Other / comorbidity
NCT07157306 · Tianjin Medical University Cancer Institute and Hospital
2025-09-10 – 2028-01-01 · Hepatocellular Carcinoma
What this study did
NCT07197112 · Ruijin Hospital
2025-10-01 – 2027-12-01 · Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease
What this study did
NCT07185633 · Bin Gu
2026-01-01 – 2027-10-01 · aGVHD
What this study did
NCT04971551 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-12 – 2025-07 · Acute Graft-Versus-Host Disease
What this study did
NCT05686629 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-04 – 2025-03 · Novel COVID-19-Infected Pneumonia
What this study did
NCT05688839 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-04 – 2025-03 · Novel COVID-19-Infected Pneumonia
What this study did
NCT05672888 · First Affiliated Hospital of Zhejiang University
2023-03 – 2024-05 · COVID-19 Pneumonia
What this study did
NCT05702788 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2022-09 – 2024-04-23 · COVID-19, Pneumonia
What this study did
NCT04612699 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-03-11 – 2022-08-15 · Moderate-to-Severe Plaque Psoriasis
What this study did
NCT04507659 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-12-01 – 2022-08-02 · Ankylosing Spondylitis
What this study did
NCT04312594 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-09-08 – 2022-06-09 · Idiopathic Pulmonary Fibrosis
What this study did
Phase 1/2 (12) Alopecia Areata
NCT04445363 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-08-12 – 2024-12-01 · Alopecia Areata(AA)
What this study did
Atopic Dermatitis
NCT04435392 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2020-10-14 – 2022-09-08 · Atopic Dermatitis
What this study did
Myelofibrosis
NCT07883382 · Ruijin Hospital
2026-10-15 – 2029-09-30 · Myeloid Neoplasms With Myelofibrosis
What this study did
NCT04866056 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-09-30 – 2022-06-10 · Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Myelofibrosis
What this study did
Other / comorbidity
NCT07012304 · Yujun DONG
2025-06-30 – 2029-02-28 · Chronic Graft Versus Host Disease
What this study did
NCT07476872 · Institute of Hematology & Blood Diseases Hospital, China
2026-03-16 – 2028-11-01 · cGVHD, HSCT
What this study did
NCT07885228 · Nanfang Hospital, Southern Medical University
2026-10-10 – 2028-06-10 · Acute Graft vs Host Disease
What this study did
NCT07285889 · First Affiliated Hospital of Zhejiang University
2025-12-03 – 2027-12-31 · Acute Graft Versus Host Disease
What this study did
NCT07142837 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-09 – 2027-12 · Advanced Solid Tumor
What this study did
NCT07080216 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-09-23 – 2027-12 · Cervical Cancer
What this study did
NCT06903377 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-05-23 – 2027-05 · Non-small Cell Lung Cancer
What this study did
NCT06883526 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2025-05-16 – 2027-05 · Lymphoma
What this study did
Phase 1 (8) Myelofibrosis
NCT05279001 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-07-01 – 2025-11-30 · Myelofibrosis
What this study did
NCT06132243 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2023-11-29 – 2023-12-20 · Myelofibrosis
What this study did
Other / comorbidity
NCT07565597 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2026-05-12 – 2027-03 · Healthy
What this study did
NCT06193148 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2024-03-19 – 2024-06-18 · Healthy Participants
What this study did
NCT04993404 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-08-27 – 2022-09-19 · Hepatic Insufficiency, Healthy Subjects
What this study did
NCT05150717 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2022-01-04 – 2022-01-30 · Healthy Adult Male Volunteers
What this study did
NCT06246695 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2021-10-27 – 2022-01-12 · Healthy Volunteers
What this study did
NCT03314402 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd
2017-09-28 – 2018-09-27 · Healthy Volunteers
What this study did
Early phase / not applicable (4) Myelofibrosis
NCT07440654 · Nanfang Hospital, Southern Medical University
2026-03-01 – 2029-12-01 · aGVHD Prophylaxis
What this study did
NCT07904871 · First Affiliated Hospital of Zhejiang University
2026-11-01 – 2029-11-01 · Myelofibrosis, Primary Myelofibrosis (PMF), Secondary Myelofibrosis
What this study did
Other / comorbidity
NCT07454226 · Institute of Hematology & Blood Diseases Hospital, China
2026-05-30 – 2030-03-01 · Ph-Like, Acute Lymphoblastic Leukemia
What this study did
NCT07445893 · Duan Minghui
2026-04-02 – 2028-12-30 · Polycythemia Vera (PV)
What this study did
Competitive landscape Alopecia Areata Atopic Dermatitis Myelofibrosis List view
This drug's own stage for Alopecia Areata: Phase 3 . Competitors below are sorted furthest-along first.
Upcoming events (19 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Email me about these readouts Follow Zepuping (jaktinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (1) December 2026 (1) Early phase / not applicable Polycythemia Vera (PV) Recruiting
Est. primary completion 2026-12-30 ·
NCT07445893 ·
CT.gov ↗ What to watch
2027 (12) January 2027 (1) Phase 2 Hepatocellular Carcinoma Not yet recruiting
Est. primary completion 2027-01-01 ·
NCT07157306 ·
CT.gov ↗ What to watch
February 2027 (3) Phase 1 Healthy Active not recruiting
Est. primary completion 2027-02 ·
NCT07565597 ·
CT.gov ↗ What to watch
Phase 2 Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease Not yet recruiting
Est. primary completion 2027-02-01 ·
NCT07197112 ·
CT.gov ↗ What to watch
Phase 1/2 Chronic Graft Versus Host Disease Recruiting
Est. primary completion 2027-02-28 ·
NCT07012304 ·
CT.gov ↗ What to watch
April 2027 (2) Phase 1/2 Non-small Cell Lung Cancer Recruiting
Est. primary completion 2027-04 ·
NCT06903377 ·
CT.gov ↗ What to watch
Phase 1/2 Lymphoma Recruiting
Est. primary completion 2027-04 ·
NCT06883526 ·
CT.gov ↗ What to watch
June 2027 (1) Phase 1/2 Acute Graft vs Host Disease Not yet recruiting
Est. primary completion 2027-06-10 ·
NCT07885228 ·
CT.gov ↗ What to watch
August 2027 (1) Phase 1/2 Cervical Cancer Recruiting
Est. primary completion 2027-08 ·
NCT07080216 ·
CT.gov ↗ What to watch
October 2027 (2) Phase 1/2 Advanced Solid Tumor Not yet recruiting
Est. primary completion 2027-10 ·
NCT07142837 ·
CT.gov ↗ What to watch
Phase 2 aGVHD Recruiting
Est. primary completion 2027-10-01 ·
NCT07185633 ·
CT.gov ↗ What to watch
November 2027 (1) Phase 1/2 cGVHD, HSCT Not yet recruiting
Est. primary completion 2027-11-01 ·
NCT07476872 ·
CT.gov ↗ What to watch
December 2027 (1) Phase 1/2 Acute Graft Versus Host Disease Recruiting
Est. primary completion 2027-12-31 ·
NCT07285889 ·
CT.gov ↗ What to watch
2028 (4) March 2028 (1) Early phase / not applicable Ph-Like, Acute Lymphoblastic Leukemia Recruiting
Est. primary completion 2028-03-01 ·
NCT07454226 ·
CT.gov ↗ What to watch
October 2028 (1) Phase 1/2 Myelofibrosis Recruiting
Est. primary completion 2028-10-28 ·
NCT07883382 ·
CT.gov ↗ What to watch
November 2028 (1) Early phase / not applicable Myelofibrosis Not yet recruiting
Est. primary completion 2028-11-01 ·
NCT07904871 ·
CT.gov ↗ What to watch
December 2028 (1) Phase 2 Myelofibrosis Not yet recruiting
Est. primary completion 2028-12 ·
NCT07938580 ·
CT.gov ↗ What to watch
2029 (2) April 2029 (1) Phase 2 Myelofibrosis Not yet recruiting
Est. primary completion 2029-04-01 ·
NCT07471503 ·
CT.gov ↗ What to watch
September 2029 (1) Early phase / not applicable Myelofibrosis Not yet recruiting
Est. primary completion 2029-09-01 ·
NCT07440654 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (3) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
13 April 2026 Topline result ZGJAK025 (NCT05526222) Phase 3 in moderate-to-severe atopic dermatitis met its primary endpoints
Suzhou Zelgen Biopharmaceuticals Co., Ltd. ·
Source ↗ 21 October 2025 Topline result ZGJAK029 (NCT05861102) Phase 3 in active ankylosing spondylitis met its primary endpoint
苏州泽璟生物制药股份有限公司 (Suzhou Zelgen Biopharmaceuticals Co., Ltd.) ·
Source ↗ 13 June 2024 Topline result ZGJAK018 (NCT05051761) Phase 3 in severe alopecia areata met its primary endpoint
苏州泽璟生物制药股份有限公司 (Suzhou Zelgen Biopharmaceuticals Co., Ltd.) ·
Source ↗